Tralokinumab is a humanized monoclonal antibody developed by MedImmune LLC (now a subsidiary of AstraZeneca, since 2007), aimed at treating asthma and inflammatory conditions. It was discovered by Cambridge Antibody Technology (CAT: A biotechnology company using phage display and ribosome display technology to develop therapeutics, now a subsidiary of AstraZeneca) under the name CAT-354.
History of Tralokinumab
The preclinical studies performed to test the capacities of CAT-354 as a drug were undertaken by CAT itself. After AztraZeneca’s acquisition of both CAT and MedImmune LLC in 2006 and 2007 respectively, MedImmune acquired the license to develop the drug and put it into further investigational studies. In March 2008, a study was initiated by MedImmune to test the bioavailability and pharmacokinetics of CAT-354. In 2011, a phase IIb randomized clinical trial was initiated by MedImmune to test the drug’s efficiency in treating patients with asthma, followed by AstraZeneca’s decision to collaborate with MedImmune and host a phase II trial to test the efficacy of Tralokinumab in patients with moderate to severe ulcerative colitis.
How Tralokinumab Works
Tralokinumab inhibits the secretion of Interleukin 13 (IL-13) from Th2 cells in blood. IL-13 is responsible for secretion of high amounts of periostin protein, which is responsible for adhesion and migration of epithelial cells in the bronchi, bronchial hyper-responsiveness, activation and proliferation of fibroblasts, and several other factors involved in airway remodeling. As a result, IL-13 represents a formidable target for respiratory conditions.
Next Steps For Tralokinumab
In October 2012, a Phase II, Randomized Dose-ranging Study to evaluate the efficacy of Tralokinumab in adults with Idiopathic Pulmonary Fibrosis (IPF) was initiated, with a total of 186 patients enrolled, all between 50 and 79 years of age, with moderately severe case histories of IPF. The final results are expected by October 2016.